Catch up on today’s top five analyst upgrades with this list compiled by The Fly: 1. Royalty Pharma (RPRX) upgraded to Buy from Neutral at UBS with analyst Navin Jacob saying “creative transactions,” such as the Biohaven Pharmaceutical (BHVN) financing and Cystic Fibrosis deal, increases the likelihood of low double digit returns on new investments. 2. Yelp (YELP) upgraded to Neutral from Sell at UBS with analyst Eric Sheridan citing improved trends and management execution for the upgrade. 3. Albemarle (ALB) upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar saying his analysis shows that lithium supply/demand “should meaningfully tighten” over the next two years. 4. Lear (LEA) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he sees “a solid combo” of a thriving seating business with an e-systems opportunity that is well positioned for expected battery electric vehicle growth. 5. TrueCar (TRUE) upgraded to Outperform from Market Perform at JMP Securities with analyst Andrew Boone saying that the 26% decline in the stock has made its risk/reward “compelling” and “extremely favorable”. This list is just a portion of The Fly’s full analyst coverage. To see The Fly’s full Street Research coverage, (click here.):(http://thefly.com/streetResearch.php)
previous post
next post